In a landmark laboratory study, Japanese researchers have successfully removed the extra chromosome responsible for Down syndrome using CRISPR-Cas9, restoring typical cell function and slowing cellular aging. The study, which utilized allele-specific editing, represents the first time that the full removal of the trisomy 21 chromosome has been accomplished in human cells in vitro.
Although the work is far from being tested in humans, the implications are profound: the edited cells showed normalized gene activity, improved metabolic function, and reactivated pathways involved in neural development.
Restoring balance in cellular function
The study, conducted by researchers from several Japanese institutions, used CRISPR-Cas9 gene editing to target and remove the third copy of chromosome 21 from skin fibroblast cells of an individual with Down syndrome. These cells were then compared with unedited Down syndrome cells.
The findings were striking. Following removal of the trisomy, cells reverted to normal patterns of protein production. Genes related to metabolism—which tend to be overactive in Down syndrome—were toned down, while genes important for neural development and cellular repair were reactivated.
“Normal cell function was observed in those which had their extra trisomy 21 removed,” the authors noted. “They reverted to typical patterns of protein manufacturing, showed better survival rates, and more fitness-promoting expression of genes.”
This aligns with earlier observations that trisomy 21 leads to a consistent state of metabolic overactivity, producing excessive reactive oxygen species (ROS)—a form of cellular waste that contributes to inflammation and accelerated aging. For individuals with Down syndrome, this imbalance is linked to heightened risks of cardiovascular disease, Alzheimer’s disease, and shortened life expectancy.
A slow but steady climb in longevity
The life expectancy of individuals with Down syndrome has drastically increased over the last century. In 1900, people with the condition lived an average of just 9 years. By 1984, life expectancy had climbed to 28 years. Today, thanks to improvements in pediatric cardiac surgery, general healthcare, and advocacy, individuals with Down syndrome routinely live into their 50s and 60s.
However, as noted by the Adult Down Syndrome Center, this progress has begun to plateau. The surge in age-related neurological conditions, particularly Alzheimer’s, has become a major obstacle to continued gains.
“That progress has significantly leveled off, driven by a strong risk of Alzheimer’s and dementias in Down Syndrome patients as they reach late-middle age,” the researchers explained.
These challenges have prompted scientists to explore how trisomy 21 may affect aging and cellular degeneration—and how genetic tools might mitigate those effects.
Societal implications and ethical questions
Despite the excitement around the research, the authors emphasize that their work is strictly preliminary. The CRISPR technique has only been used in laboratory-grown cells, and significant biological and ethical questions remain. One central issue is how such an intervention could be applied across all cells in a developing fetus, particularly in non-dividing cells like neurons.
Another key point is that, despite widespread awareness of trisomy 21’s genetic basis—which has been understood for over five decades—the number of individuals living with Down syndrome in the U.S. has continued to rise. According to recent CDC data, approximately 1 in 700 babies in the U.S. are born with the condition. This represents a quadrupling of the Down syndrome population during a period when the general U.S. population only doubled.
This suggests that the societal and environmental drivers of trisomy 21 expression may be more complex and persistent than previously recognized.
A complex condition, not a simple target
Understandably, many families and advocates within the Down syndrome community are wary of any language that suggests a “cure.” To them, Down syndrome is not simply a genetic mistake to be corrected, but part of their children’s identity.
The researchers acknowledge this complexity. They are not suggesting a clinical path forward, nor are they advocating for widespread application of their findings.
“The findings do not indicate a direct path toward a therapy,” said the lead author. “And the method should be tested in more studies.” (Dr. Yasuhiro Kazuki, one of the study’s senior authors, as cited in the research).
There are also scientific limitations to consider. Many types of cells in the body are non-dividing. If CRISPR editing is to be applied as a future therapy, it may require targeting all affected cells—a feat that is currently not possible with today’s technology.
Still, as CRISPR technology continues to evolve, the ability to manipulate chromosomes with such precision represents a fundamental leap forward in our understanding of genetic disorders. Whether or not it leads to therapies, this study marks a crucial turning point in exploring the role of trisomy 21 in the biology of Down syndrome.
While the road to potential treatment remains uncertain and controversial, one thing is clear: the field of gene editing has crossed a major milestone.
Recommended For You
